
    
      This trial is a single arm, non-randomized prospective trial. Following histotripsy treatment
      of liver tumor(s), subjects will undergo imaging â‰¤36 hours post-index procedure to determine
      technical success. Subjects will then be followed for 30 days. Data through the 30-day time
      point will be used for a Regulatory Submission to the Notified Body. Additionally, subjects
      will be followed for one (1) year post-index procedure, with evaluations at the 6-month and
      1-year time points to estimate the efficacy and safety profile of the HistoSonics System as
      part of post-market clinical follow-up.
    
  